Abbott files infringement suit for paricalcitol against Teva

Abbott Laboratories et al. (Plaintiffs) have filed an infringement suit against Teva Parenteral Medicines Inc. et al (Defendants) for infringement of U.S. Patent Nos. 5,246,925 (“the ’925 patent”); 5,587,497 (“the ’497 patent”); and 6,136,799 (“the ’799 patent”). This action arises out of Teva’s filing of an Abbreviated New Drug Application (“ANDA”) seeking approval to sell a generic copy of Abbott’s highly successful Zemplar® injectable products prior to the expiration of patents owned by and exclusively licensed to Plaintiffs. The case was filed on November 19, 2009 in the District Court of Delaware. The details of the complaint are available here